✦ LIBER ✦

CV4 ASSESSING COST-EFFECTIVENESS BEFORE MARKETING: A CASE-STUDY OF RIMONABANT FOR REDUCTION OF CARDIOMETABOLIC RISK IN PATIENTS WITH DYSLIPIDEMIA IN THE UK

✍ Scribed by JJ Caro; D Getsios; I Proskorovsky; C Nicholls; P McEwan

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

POB4 USE OF GROWTH CURVE ANALYSES FOR DI

✍ JJ Caro; KJ Ishak; D Getsios; J Moller; V Lavaud 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PUK14 CHALLENGES IN ASSESSING COST-EFFEC

✍ D Grima; D Mendelssohn; P Airia; E Dunn; L Bernard 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Cost-effectiveness of losartan-based the

✍ McInnes, G; Burke, T A; Carides, G 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

PCV51 Cost-Effectiveness of Rivaroxaban

✍ Y. Asukai; A. Duran; A. Lloyd; E.J. McLeod; T. Evers; J. Broughton 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB